Akut pankreatit (AP) är sannolikt en av huvudorsakerna till sjukhusinläggning, varav 20% kan utvecklas till den extrema sorten med djupgående acinarcellnekros. Medicinsk forskning har rapporterat att diabetes är en opartisk riskfråga om förekomsten av AP och är relaterad till ökad svårighetsgrad än ämnen utan diabetes. Men hur diabetes deltar i AP -utvecklingen beskrivs inte effektivt.
För att analysera denna fråga hade vildtyp (wt) och diabetiska db/db-möss vid 16 veckors ålder använts inom forskningen. AP inducerades i viktmottagare med 10 injektioner av 50 μg /kg caerulein med ett intervall på 1 timme. En timme efter den sista caerulein -injektionen hade benmärgsceller (BMC) remoterade från wt- och db/db -möss injicerats intraperitonealt i mottagarna (1 x 107 celler/mottagare).
Mottagarna utan BMC -injektion fungerade som kontroller. 13 timmar efter BMC-injektion ökade serumlipasövningen 1,8- och 1,3-faldigt hos möss som förvärvade db/db BMC, i motsats till dessa utan injektion respektive BMC-injektion ( p ≤ 0,02 för varje).
Genom H & E -färgning var den allmänna allvarlighetsgraden 14,7 för ingen cellinjektion och 16,6 för BMC -injektion i vikt och förhöjd till 22,6 för db/db BMC -injektion ( p ≤ 0,002 för varje). Specifikt utvecklade möss med db/db BMC -injektion extra acinarcellnekros och vakuolisering än motsatta lag ( p ≤ 0,03 för varje).
När sektioner hade färgats med en antikropp i motsats till myeloperoxidas ( MPO ) var densiteten hos MPO + -celler vid pankreatit 1,9- och 1,6-faldig ökad än vikt BMC och inga BMC-injektionsteam, individuellt ( p ≤ 0,02 för varje).
Kvantifierat med ELISA , db/db BMC producerade extra IL-6, GM-CSF och IL-10 i motsats till vikt BMC ( p ≤ 0,04 för alla). Sammanfattningsvis producerade BMC för db/db -möss extra inflammatoriska cytokiner. Som svar på acinar cellskada förvärrade diabetisk BMC irritationskaskaden och acinar cellskador, vilket resulterade i utvecklingen av akut pankreatit.
Corynoline skyddar lipopolysackaridinducerad mastit genom att reglera AKT/GSK3β/Nrf2 signalväg
Irritation har identifierats vara oroande vid patogenesen av mastit. Och antiinflammatoriskt medel föreslås vara en uppnåelig miljövänlig terapeutisk teknik för mastit. Corynoline, en bioaktiv förening extraherad från Corydalis bungeana Turcz., Har rapporterats ha antiinflammatorisk effekt.
Huruvida korynolin har en skyddande effekt i motstånd mot mastit förblir dock oklart. Avsikten med denna forskning var att bedöma den skyddande effekten av korynolin på LPS-inducerad mastit hos möss. Inflammatorisk cytokintillverkning mättes med ELISA . Proteinerna i signalvägar hade detekterats genom western blot -utvärdering.
Resultaten bekräftade att botemedel mot korynolin vid doserna 15, 30 och 60 mg/kg avsevärt försvagade LPS-inducerad patologisk skada på bröstvävnader. Korynolin förbättrade dessutom LPS-inducerad MPO- träning, MDA-innehållsmaterial och inflammatorisk cytokin TNF-a och IL-1β-tillverkning i bröstvävnader.
LPS-inducerad NF-KB-aktivering inhiberades av korynolin. Dessutom bekräftade våra resultat korynolin avsevärt uttrycket av Nrf2 och fosforyleringsintervallet för AKT och GSK3β. Sammanfattningsvis indikerade våra resultat att korynolin skyddade mot LPS-inducerad mastit genom att reglera AKT/GSK3β/Nrf2 signalväg, vilket senare ledde till inhibering av NF-KB och inflammatoriskt svar.
Taohong Siwu -avkok reglerar cellnekros och neuroinflammation inom råttcentret Cerebral Artery Occlusion Mannequin
Cellnekros och neuroinflammation spelar en nödvändig funktion för att tänka på skador som orsakas av ischemisk stroke. Tidigare forskning har rapporterat att Taohong Siwu-avkok (THSWD) kan skala ner koronar hjärtmuskelnekros och har antiinflammatoriska egenskaper. På denna forskning undersökte vi konsekvenserna av THSWD på cellnekros och neuroinflammation i en råttdocka med center cerebral arterie occlusion (MCAO).
Trettiosex hanråttor Sprague-Dawley (SD) hade slumpmässigt delats in i tre lag med 12 råttor i varje grupp. De hade varit skenoperationsgruppen, MCAO -mannequingruppen och MCAO + THSWD -gruppen. Vi använde ELISA för att ta reda på graderna av TNF-α, Mcp-1 och IL-1β inflammatoriska element i råttserum, qRT-PCR för att detektera uttrycket av TNF-α, Mcp-1 och IL-1β mRNA i råtta , och immunhistokemi för att upptäcka variationen av mikroglia och neutrofiler i råtta. qRT-PCR och Western blot hade använts för att detektera mRNA- och proteinuttrycksintervall för IBA- 1- och MPO- inflammatoriska element och TNF-a/RIP1/RIP3/MLKL-vägen inom råttans sinne och proteinuttrycksintervall.
I motsats till skenoperationsgruppen hade uttrycket av MCP-1, IL-1β, IBA-1 och MPO inflammatoriska element och TNF-a/RIP1/RIP3/MLKL-vägen väsentligt uppreglerats inom MCAO-gruppen. I motsats till MCAO-gruppen hade uttrycken av MCP-1, IL-1β, IBA-1 och MPO- inflammatoriska element och TNF-α/RIP1/RIP3/MLKL-vägen avsevärt nedreglerats inom MCAO + THSWD-gruppen.
THSWD kan skala tillbaka uttrycksintervallen för MCP-1, IL-1β, IBA-1 och MPO inflammatoriska element utöver TNF-α/RIP1/RIP3/MLKL-vägen. Under tiden kan det eventuellt skala ner nekros och irritation av hjärnceller efter cerebral ischemi, för att skydda hjärnvävnaden hos råttor.
Dihydrotanshinon dämpar LPS-inducerad akut lungskada hos möss genom uppreglering av LXRα
Dihydrotanshinon (DIH) är ett extrakt av Salvia miltiorrhiza Bunge. Det har rapporterats att DIH kan reglera NF-KB-signalvägen. Avsikten med denna forskning var att undersöka huruvida DIH kan skydda möss från lipopolysackarid (LPS) -inducerad akut lungskada (ALI) hos möss. I denna forskning hade sextio möss slumpmässigt delats in i 5 lag, en grupp som ren ledningsgrupp, den andra gruppen som LPS-ledningsgrupp och de tre sista lagen hade förinjicerats med helt olika doser av DIH, varefter inandade LPS för experimentell jämförbarhet.
Efter 12 timmars behandling med LPS hade våt-torr-förhållandet, histopatologiska justeringar och myeloperoxidas ( MPO ) övning av lungorna mätts. Förutom hade ELISA- kit använts för att mäta graderna av TNF-α och IL-1β inflammatoriska cytokiner i bronkoalveolära sköljvätskor (BALF), och western blot-utvärdering användes för att mäta utövandet av NF-κB-signalväg.
Resultaten visade att DIH framgångsrikt skulle kunna minska lungödem, MPO -träning och förbättra lunghistopatologiska justeringar. Dessutom undertryckte DIH graderna av inflammatoriska cytokiner i BALF, liknande TNF-α och IL-1β.
Förutom att DIH ytterligare kan nedreglera utövandet av NF-κB-signalvägen. Vi upptäckte dessutom att DIH dosberoende höjde uttrycket av LXRa. Likaså kan DIH hämma LPS-inducerad IL-Eight-tillverkning och NF-KB-aktivering i A549-celler.
Och de hämmande resultaten hade reverserats av LXRa -hämmare geranylgeranylpyrofosfat (GGPP). På grund av detta faktum spekulerar vi att DIH reglerar LPS-inducerat ALI hos möss genom att öka LXRa-uttryck, vilket därefter hämmar NF-KB-signalvägen.
Protectin D1 skyddar i motsats till lipopolysackaridinducerad akut lungskada genom hämning av neutrofilinfiltration och bildandet av neutrofila extracellulära fällor i lungvävnad
Protectin D1 (PD1), en DHA-härledd lipidförmedlare, har inte för länge sedan visat sig ha antiinflammatoriska och pro-upplösande egenskaper. Hittills är lite förstått om PD1: s inverkan på lipopolysackarid (LPS) -inducerad akut lungskada (ALI) hos möss.
Avsikten med den aktuella forskningen var att undersöka de terapeutiska resultaten av PD1 på LPS-inducerad ALI och dess potentiella rörelsemekanismer. ALI inducerades genom en intraperitoneal injektion av LPS, platsen PD1 (2 ng/mus) administrerades intravenöst 30 minuter efter LPS -problem. Möss hade offrats 24 timmar efter modellering.
Lunghistopatologiska justeringar hade utvärderats med hjälp av hematoxylin och eosinfärgning och myeloperoxidas ( MPO ) träning undersöktes med hjälp av immunhistokemi. Tumörnekros-α och interleukin-6-intervall inom bronkoalveolär sköljvätska (BALF) och serum hade mätts med ELISA .
För att detektera neutrofila extracellulära fällor producerade av infiltrerade neutrofiler i lungvävnaden utfördes immunofluorescensfärgning med användning av anti- MPO- och anti-histon H3-antikroppar. Resultaten indikerade att PD1 avsevärt dämpade histologisk skada och neutrofilinfiltration i lungvävnad, minskade lungfukt/torrviktsförhållandet, proteinfokus och proinflammatoriska cytokinintervall i BALF och minskade proinflammatoriska cytokinintervall i serum.
Human Polymeric Immunoglobulin Receptor Secretory Component (PIGR) ELISA Kit |
|||
| abx250740-96tests | Abbexa | 96 tests | EUR 848.4 |
Human PIGR(Polymeric Immunoglobulin Receptor/Membrane Secretory Component) ELISA Kit |
|||
| EH1460 | FN Test | 96T | EUR 628.92 |
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 18.75pg/ml |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCA0050-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IgA Secretory Component(SC05), APC conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC800050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF680 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC800050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF680 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC810050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF680R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC810050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF680R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC940050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF594 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC940050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF594 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC880050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF488A conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC880050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF488A conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC430050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF543 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC430050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF543 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC400050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF640R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC400050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF640R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC050050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF405M conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC050050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF405M conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCB0050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Biotin conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCB0050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Biotin conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCAP0050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCAP0050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCR0050-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IgA Secretory Component(SC05), RPE conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNUB0050-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Concentration: 0.2mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNUB0050-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Concentration: 0.2mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCP0050-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IgA Secretory Component(SC05), PerCP conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCH0050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNUM0050-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against IgA Secretory Component(SC05), 1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNCH0050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC040050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF405S conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC040050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF405S conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC550050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF555 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC550050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF555 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC610050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF660R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC610050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF660R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC680050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF568 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC680050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF568 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC470050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF647 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC470050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF647 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC700050-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF770 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(SC05) Antibody |
|||
| BNC700050-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(SC05), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V9015-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V9015-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V9015IHC-7ML | NSJ Bioreagents | 7 ml | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V9015SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V3979-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V3979-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V3979IHC-7ML | NSJ Bioreagents | 7 ml | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V3979SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V7065-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Extracellular matrix protein 1 (ECM1), also called Secretory component p85, a soluble protein that is involved in endochondral bone formation, angiogenesis, and tumor biology. It also interacts with a variety of extracellular and structural proteins, contributing to the maintenance of skin integrity and homeostasis. Mutations in this gene are associated with lipoid proteinosis disorder (also known as hyalinosis cutis et mucosae or Urbach-Wiethe disease) that is characterized by generalized thickening of skin, mucosae and certain viscera. [RefSeq] |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V7065-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: Extracellular matrix protein 1 (ECM1), also called Secretory component p85, a soluble protein that is involved in endochondral bone formation, angiogenesis, and tumor biology. It also interacts with a variety of extracellular and structural proteins, contributing to the maintenance of skin integrity and homeostasis. Mutations in this gene are associated with lipoid proteinosis disorder (also known as hyalinosis cutis et mucosae or Urbach-Wiethe disease) that is characterized by generalized thickening of skin, mucosae and certain viscera. [RefSeq] |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V7065IHC-7ML | NSJ Bioreagents | 7 ml | EUR 349.3 |
|
Description: Extracellular matrix protein 1 (ECM1), also called Secretory component p85, a soluble protein that is involved in endochondral bone formation, angiogenesis, and tumor biology. It also interacts with a variety of extracellular and structural proteins, contributing to the maintenance of skin integrity and homeostasis. Mutations in this gene are associated with lipoid proteinosis disorder (also known as hyalinosis cutis et mucosae or Urbach-Wiethe disease) that is characterized by generalized thickening of skin, mucosae and certain viscera. [RefSeq] |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V7065SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Extracellular matrix protein 1 (ECM1), also called Secretory component p85, a soluble protein that is involved in endochondral bone formation, angiogenesis, and tumor biology. It also interacts with a variety of extracellular and structural proteins, contributing to the maintenance of skin integrity and homeostasis. Mutations in this gene are associated with lipoid proteinosis disorder (also known as hyalinosis cutis et mucosae or Urbach-Wiethe disease) that is characterized by generalized thickening of skin, mucosae and certain viscera. [RefSeq] |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2484-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2484-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2484IHC-7ML | NSJ Bioreagents | 7 ml | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2484SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This mAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2104-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This antibody reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory component. It does not react with the cell lines lacking this protein. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2104-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: This antibody reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory component. It does not react with the cell lines lacking this protein. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2104IHC-7ML | NSJ Bioreagents | 7 ml | EUR 349.3 |
|
Description: This antibody reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory component. It does not react with the cell lines lacking this protein. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V2104SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This antibody reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory component. It does not react with the cell lines lacking this protein. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V8508-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This MAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V8508-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: This MAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Secretory Component p85 Antibody / ECM1 |
|||
| V8508SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: This MAb reacts with a reduction-resistant epitope present in both free and SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution and level of both free and bound secretory component. Secretory component is differentially expressed in epithelium, and the antibody is a popular marker for identifying subpopulations of epithelial cells and epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation and tumorigenesis, all processes associated with differential secretory component expression. |
|||
Human polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| 201-12-0321 | SunredBio | 96 tests | EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
|||
Human polymeric immunoglobulin receptor/secretory component(PIGR/SC)ELISA Kit |
|||
| GA-E0337HM-48T | GenAsia Biotech | 48T | EUR 346.8 |
Human polymeric immunoglobulin receptor/secretory component(PIGR/SC)ELISA Kit |
|||
| GA-E0337HM-96T | GenAsia Biotech | 96T | EUR 559.2 |
Human polymeric immunoglobulin receptor/secretory component(PIGR/SC)ELISA Kit |
|||
| QY-E03735 | Qayee Biotechnology | 96T | EUR 480 |
Human polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA0405HU-48T | Shanghai YL Biotech | 48T | EUR 435 |
Human polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA0405HU-96T | Shanghai YL Biotech | 96T | EUR 562.5 |
Anti-IgA Secretory Component antibody |
|||
| STJ16101011 | St John's Laboratory | 100 µg | EUR 424.8 |
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC800792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF680 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC800792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF680 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC810792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF680R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC810792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF680R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC940792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF594 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC940792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF594 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC700792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF770 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC700792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF770 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC880792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF488A conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC880792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF488A conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC050792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF405M conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC050792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF405M conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC040792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF405S conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC040792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF405S conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC400792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF640R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC400792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF640R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCB0792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Biotin conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCB0792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Biotin conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCAP0792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCAP0792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCA0792-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), APC conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCR0792-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), RPE conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCP0792-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), PerCP conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNUM0792-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), 1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCH0792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNCH0792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNUB0792-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Concentration: 0.2mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNUB0792-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), Concentration: 0.2mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC610792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF660R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC610792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF660R conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC550792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF555 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC550792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF555 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC430792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF543 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC430792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF543 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC680792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF568 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC680792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF568 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC470792-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF647 conjugate, Concentration: 0.1mg/mL |
|||
IgA Secretory Component(ECM1/792) Antibody |
|||
| BNC470792-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IgA Secretory Component(ECM1/792), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component; Clone SC05 (Concentrate) |
|||
| A00127-C | ScyTek Laboratories | 1 ml | EUR 524.4 |
Anti-Hu IgA Secretory Component Purified |
|||
| 11-112-C025 | ExBio | 0.025 mg | EUR 108 |
Anti-Hu IgA Secretory Component Purified |
|||
| 11-112-C100 | ExBio | 0.1 mg | EUR 168 |
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC942889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC942889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC802889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC802889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC702889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC702889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC882889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC882889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC812889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC812889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC402889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC402889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC052889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC052889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC042889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC042889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCAP2889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCAP2889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCA2889-250 | Biotium | 250uL | EUR 472.8 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), APC conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCP2889-250 | Biotium | 250uL | EUR 472.8 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCR2889-250 | Biotium | 250uL | EUR 472.8 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), RPE conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCH2889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCH2889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCB2889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNCB2889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNUB2889-100 | Biotium | 100uL | EUR 316.8 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Concentration: 0.2mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNUB2889-50 | Biotium | 50uL | EUR 486 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), 1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNUB2889-500 | Biotium | 500uL | EUR 615.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), Concentration: 0.2mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC472889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC472889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC552889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC552889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC612889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC612889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC432889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC432889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC682889-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Secretory Component / ECM1 (ECM1/2889R) Antibody |
|||
| BNC682889-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against Secretory Component / ECM1 (ECM1/2889R), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Pig Polymeric Immunoglobulin Receptor Secretory Component (PIGR) ELISA Kit |
|||
| abx361789-96tests | Abbexa | 96 tests | EUR 990 |
Rabbit Polymeric Immunoglobulin Receptor Secretory Component (PIGR) ELISA Kit |
|||
| abx362612-96tests | Abbexa | 96 tests | EUR 990 |
Sheep Polymeric Immunoglobulin Receptor Secretory Component (PIGR) ELISA Kit |
|||
| abx364561-96tests | Abbexa | 96 tests | EUR 1111.2 |
Monkey Polymeric Immunoglobulin Receptor Secretory Component (PIGR) ELISA Kit |
|||
| abx359522-96tests | Abbexa | 96 tests | EUR 990 |
Secretory Component / ECM1; Clone SC05 (Concentrate) |
|||
| RA0105-C.1 | ScyTek Laboratories | 0.1 ml | EUR 150 |
Secretory Component / ECM1; Clone SC05 (Concentrate) |
|||
| RA0105-C.5 | ScyTek Laboratories | 0.5 ml | EUR 360 |
Rat polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA1266RA-48T | Shanghai YL Biotech | 48T | EUR 465 |
Rat polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA1266RA-96T | Shanghai YL Biotech | 96T | EUR 600 |
Chicken Polymeric Immunoglobulin Receptor Secretory Component (PIGR) ELISA Kit |
|||
| abx356658-96tests | Abbexa | 96 tests | EUR 990 |
ELISA kit for Human PIGR/SC (Polymeric Immunoglobulin Receptor/Membrane Secretory Component) |
|||
| E-EL-H1236 | Elabscience Biotech | 1 plate of 96 wells | EUR 640.8 |
|
Description: A sandwich ELISA kit for quantitative measurement of Human PIGR/SC (Polymeric Immunoglobulin Receptor/Membrane Secretory Component) in samples from Serum, Plasma, Cell supernatant |
|||
Secretory Component; Clone SC05 (Ready-To-Use) |
|||
| A00127-0002 | ScyTek Laboratories | 2 ml | EUR 82.8 |
Secretory Component; Clone SC05 (Ready-To-Use) |
|||
| A00127-0007 | ScyTek Laboratories | 7 ml | EUR 114 |
Secretory Component; Clone SC05 (Ready-To-Use) |
|||
| A00127-0025 | ScyTek Laboratories | 25 ml | EUR 225.6 |
Rabbit polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA0166RB-48T | Shanghai YL Biotech | 48T | EUR 465 |
Rabbit polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA0166RB-96T | Shanghai YL Biotech | 96T | EUR 600 |
Bovine polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA0247BO-48T | Shanghai YL Biotech | 48T | EUR 502.5 |
Bovine polymeric immunoglobulin receptor/secretory component,PIGR/SC ELISA Kit |
|||
| YLA0247BO-96T | Shanghai YL Biotech | 96T | EUR 618.75 |
Vidare minskades neutrofilcitrullinerat histon H3 (CitH3) -uttryck ytterligare efter PD1 -administrering. Sammanfattningsvis försvagade PD1 LPS-inducerat ALI hos möss genom hämning av neutrofil extracellulär lockande bildning i lungvävnad. På grund av detta kan PD1 -administration vara en helt ny teknik för behandling av ALI.
